CerebroTech Medical Systems is a pioneering medical technology company focused on developing and commercializing innovative solutions for the diagnosis, monitoring, and treatment of complex neurological disorders. We leverage cutting-edge advancements in neuro-imaging, artificial intelligence, and bio-sensor technology to create tools that empower clinicians, improve patient outcomes, and advance the understanding of brain health. Our commitment is to push the boundaries of neuroscience to address unmet medical needs in areas such as stroke, epilepsy, traumatic brain injury, and neurodegenerative diseases.
Serves as the central hub for research and development, corporate strategy, global marketing, and administrative operations.
Features state-of-the-art R&D laboratories, advanced prototyping workshops, and collaborative workspaces designed to foster innovation. The building is LEED-certified, reflecting a commitment to sustainability.
A dynamic and collaborative environment that encourages innovation, continuous learning, and a patient-centric approach. Employees work in cross-functional teams to solve complex challenges in neuroscience.
Its location provides unparalleled access to world-class research institutions, leading hospitals, and a rich talent pool, fostering collaborations and partnerships critical for medical technology advancement.
CerebroTech Medical Systems supports its global operations through its headquarters in Cambridge, MA, and key regional offices in Europe (Freiburg, Germany) and Asia-Pacific (Yokohama, Japan). These locations facilitate R&D, clinical trials, regulatory compliance, sales, marketing, and customer support worldwide, ensuring our innovative neurological solutions reach patients and clinicians globally.
One Kendall Square, Building 400, Suite 500
Cambridge
MA
USA
Address: BioTechPark Freiburg, Engesserstraße 4a, 79108 Freiburg im Breisgau
To spearhead market entry and expansion within Europe, manage EU-specific regulatory compliance, and provide technical support to European customers and partners.
Address: Minato Mirai Center Building, 3-6-1 Minatomirai, Nishi-ku, Yokohama, Kanagawa 220-0012
To facilitate growth in key Asian markets, build relationships with regional key opinion leaders, and ensure products meet local regulatory and clinical standards.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Cerebrotech Medical Systems' leadership includes:
Cerebrotech Medical Systems has been backed by several prominent investors over the years, including:
CerebroTech Medical Systems has strategically expanded its executive team in the past year to support its growth phase, particularly in operations and medical affairs, with no major departures.
Discover the tools Cerebrotech Medical Systems uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
CerebroTech Medical Systems primarily utilizes the [first_initial][last]@cerebrotechmedical.com email format. For example, Jane Doe would be jdoe@cerebrotechmedical.com.
[first_initial][last]@cerebrotechmedical.com
Format
jdoe@cerebrotechmedical.com
Example
90%
Success rate
NeuroTech News • January 15, 2024
CerebroTech Medical Systems today announced the successful closure of a $50 million Series B funding round. The investment, led by Neuron Ventures with participation from existing investors, will be used to accelerate the development of its AI-driven diagnostic platform for early detection of neurodegenerative diseases and expand commercialization efforts for its flagship NeuroSight monitor....more
FDA MedTech Watch • November 08, 2023
The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to CerebroTech Medical Systems for its NeuroSight™ Advanced Brain Monitoring System. This innovative system provides real-time, non-invasive monitoring of critical brain parameters, aiding clinicians in the management of acute neurological injuries....more
Global Health Innovation Journal • July 20, 2023
CerebroTech Medical Systems announced a strategic partnership with Charité - Universitätsmedizin Berlin, one of Europe's largest university hospitals, to conduct clinical trials for its next-generation epilepsy detection technology. This collaboration aims to validate the technology's efficacy in diverse patient populations....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Cerebrotech Medical Systems, are just a search away.